Stock ARPN ARPIDA
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

ARPIDA Share Price Swiss Exchange

Equities

ARPN

Biotechnology & Medical Research

End-of-day quote Swiss Exchange
Other stock markets
- CHF - Intraday chart for ARPIDA
04-15 Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting MT
03-26 Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation MT

Financials

Sales 2022 15.54M 17.31M 1.37B Sales 2023 4.16M 4.63M 367M Capitalization 4.9M 5.46M 433M
Net income 2022 -43M -47.91M -3.8B Net income 2023 -101M -113M -8.92B EV / Sales 2022 6.5 x
Net Debt 2022 9.91M 11.05M 875M Net cash position 2023 5.84M 6.51M 515M EV / Sales 2023 -0.23 x
P/E ratio 2022
-2.02 x
P/E ratio 2023
-0.05 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 64.9%
More Fundamentals * Assessed data

Latest news about ARPIDA

Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting MT
Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation MT
Evolva Closes CHF20 Million Unit Sale to Lallemand's Danstar Ferment MT
Danstar Ferment AG completed the acquisition of Evolva AG form Evolva Holding SA. CI
Evolva Shareholders OK Unit Sale, Proposed Liquidation MT
Evolva to Seek Shareholder Nod for Unit Sale, Proposed Liquidation MT
Evolva Strikes CHF20 Million Deal to Sell Business to Lallemand's Danstar Ferment MT
Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA for CHF 30 million. CI
Evolva, Breko Sign Distribution Deal for Dietary Supplement Ingredient MT
Evolva and Breko GmbH Broaden Partnership by Signing Agreement for the Exclusive Distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam CI
Evolva Signs Distribution Deal with Chemical Group Lehvoss MT
Evolva and LEHVOSS Sign Agreement for Distribution of Veri-teTM Resveratrol in over A Dozen European Countries CI
Evolva, Nice & Green Agree to Term Amendments for CHF5 Million Facility MT
Evolva Wins Thai Regulatory Nod for Nature-based Ingredient Veri-teTM Resveratrol MT
Evolva Receives Approval for Veri-Te Resveratrol in Thailand CI
More news

Latest transcript on ARPIDA

Logo ARPIDA
Evolva Holding SA, H1 2023 Earnings Call, Aug 24, 2023
More transcripts

Analyst Recommendations on ARPIDA

Exane BNP Paribas Virtual Consumer Ingredients Conference FA
EVOLVA : Octavian Lowers Price Target on Evolva, Maintains Hold Recommendation MT
Berenberg Food Ingredients & Chemicals Conference FA
Berenberg Food Ingredients & Chemicals Conference FA
Exane BNP Paribas Consumer Ingredients Conference FA
More recommendations

Press releases ARPIDA

Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected EQ
Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected EQ
Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules EQ
Evolva : 2023 Evolva Holding AG – int liq report PU
Evolva : Audit Report Evolva Holding SA in liquidation new_signed PU
More press releases

News in other languages on ARPIDA

Est-ce que tout augmente à nouveau ?
En Direct des Marchés : BNP Paribas, Vinci, Dassault, Salesforce, Apple, Prysmian, Nike...
EN DIRECTO DESDE LOS MERCADOS: Santander, Iberdrola, Fluidra, Neinor Homes, Telefónica, Acs, Salesforce, UniCredit ...
Evolva-GV genehmigt Antrag auf Widerruf der Liquidation und der Dekotierung
Les actionnaires d'Evolva refusent la liquidation et la décotation
More news

Managers and Directors - ARPIDA

Managers TitleAgeSince
Christian Wichert CEO
 Chief Executive Officer 50 07/02/22
Gerhard Lobmaier COO
 Chief Operating Officer 55 31/12/20
Astrid Schäfer CTO
 Chief Tech/Sci/R&D Officer 51 31/12/17
Members of the board TitleAgeSince
Stephan Schindler CHM
 Chairman 60 14/04/20
Beat In-Albon BRD
 Director/Board Member 72 14/04/20
Andreas Pfluger BRD
 Director/Board Member 64 31/03/22
More insiders

Company Profile

Evolva Holding Ltd is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.
Sector
Biotechnology & Medical Research
Calendar
21/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+23.10% 52.73B
LONZA GROUP AG Stock Lonza Group AG
+37.49% 39B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+28.09% 30.38B
CELLTRION, INC. Stock Celltrion, Inc.
-12.26% 26.39B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.63% 26.08B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.05% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.31% 12.6B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.63% 11.51B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EVE Stock
  4. ARPN Stock